Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.51 is 1156% below its 5-year average of 0.05, near the low end of its 5-year range (-8.37–19.48).
As of the fiscal period ended Tuesday, June 30, 2026. 59.69% above its 12-month average of -1.26.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.51.
DEBT TO EQUITY RATIO
-0.51
DEBT TO EQUITY RATIO AVG TTM
-1.26
DEBT TO EQUITY RATIO AVG 3Y
-0.12
DEBT TO EQUITY RATIO AVG 5Y
0.05
DEBT TO EQUITY RATIO AVG 10Y
-0.39
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+59.69%
CURRENT VS 3Y AVG
-310.79%
CURRENT VS 5Y AVG
-1155.96%
CURRENT VS 10Y AVG
-31.03%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-563.55%
vs the sector median at left
Cartesian Therapeutics, Inc.
Market Cap
$204.79M
Debt to Equity Ratio
-0.51
TTM Avg
-1.26
3Y Avg
-0.12
5Y Avg
0.05
Market Cap
$206.24M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$206.37M
Debt to Equity Ratio
0.03
TTM Avg
0.03
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$208.73M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.21M
Debt to Equity Ratio
0.21
TTM Avg
0.16
3Y Avg
0.18
5Y Avg
0.12
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | $204.79M | -0.51 | -1.26 | -0.12 | 0.05 |
| Whitehawk Therapeutics Inc (WHWK)vs › | $206.24M | 0.00 | 0.01 | 0.01 | 0.01 |
| Sionna Therapeutics, Inc. (SION)vs › | $206.37M | 0.03 | 0.03 | 0.01 | 0.01 |
| Exagen Inc. (XGN)vs › | $202.17M | 2.09 | 1.95 | 1.44 | 1.12 |
| Surrozen, Inc. (SRZN)vs › | $201.52M | N/A | 0.08 | 0.11 | 0.16 |
| Pro-Dex, Inc. (PDEX)vs › | $208.17M | 0.38 | 0.42 | 0.43 | 0.50 |
| Alector, Inc. (ALEC)vs › | $200.97M | N/A | 0.76 | 0.50 | 0.39 |
| Electra Therapeutics Inc. (ETRA)vs › | $208.73M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.21M | 0.21 | 0.16 | 0.18 | 0.12 |
| Compugen Ltd. (CGEN)vs › | $211.37M | 0.03 | 0.04 | 0.03 | 0.03 |
Debt/Equity
-0.51
Current Ratio
7.48
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.51 |
| 2026-03-31 | -0.08 |
| 2025-12-31 | -0.10 |
| 2025-09-30 | -0.35 |
| 2025-06-30 | -5.28 |
| 2025-03-31 | -0.65 |
| 2024-12-31 | -2.06 |
| 2024-09-30 | 19.48 |
| 2024-06-30 | -0.15 |
| 2024-03-31 | -0.09 |
| 2023-12-31 | -0.02 |
| 2023-09-30 | 0.17 |
| 2023-06-30 | 0.53 |
| 2023-03-31 | 0.51 |
| 2022-12-31 | 0.40 |
| 2022-09-30 | 0.45 |
| 2022-06-30 | 0.39 |
| 2022-03-31 | 0.63 |
| 2021-12-31 | 1.57 |
| 2021-09-30 | -1.89 |
| 2021-06-30 | -8.37 |
| 2021-03-31 | -1.81 |
| 2020-12-31 | -1.96 |
| 2020-09-30 | -4.79 |
| 2020-06-30 | -2.04 |
| 2020-03-31 | -3.28 |
| 2019-12-31 | 2.30 |
| 2019-09-30 | -4.41 |
| 2019-06-30 | 404.16 |
| 2019-03-31 | 1.54 |
| 2018-12-31 | -3.95 |
| 2018-09-30 | 2.13 |
| 2018-06-30 | 0.87 |
| 2018-03-31 | 0.51 |
| 2017-12-31 | 0.41 |
| 2017-09-30 | 0.32 |
| 2017-06-30 | 0.13 |
| 2017-03-31 | 0.28 |
| 2016-12-31 | 0.22 |
| 2016-09-30 | 0.18 |
| 2016-06-30 | 0.17 |
| 2016-03-31 | 0.83 |
| 2015-12-31 | -0.10 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
